top of page

NEWS & INSIGHTS

Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Bite Sized News - July 10th to 14th 2023

Cell therapy data, cancer trial safety-induced hold, potential mergers, and more..

💡 Are you a CRO, CMO, or Biopharma vendor?

BiopharmIQ MarketCompass is a market intelligence tool to help with your business development. Get a free sample report of potential targets.

CLINICAL TRIAL NEWS

Adial Pharmaceuticals

Provided feedback from FDA on their drug AD04 for Alcohol Use Disorder. Two phase 3 studies may be required, and long-term safety data.


Caribou Bioscience

Reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010 (CAR-T) for r/r B-NHL. More data expected in H1 2024.


ADC Therapeutics

Voluntary pause of Phase 2 LOTIS-9 trial evaluating ZYNLONTA+ rituximab DLBCL. The pause was due to respiratory-related treatment-emergent adverse events including seven Grade 5 fatal events and five Grade 3 or Grade 4 respiratory-related TEAEs.


REGULATORY NEWS

Ardelyx

NDA for tenapanor accepted for review by China’s NMPA for the control of serum phosphorus in adult patients with chronic kidney disease on hemodialysis. This triggers a $2M milestone payment from Fosun Pharma.


M&A / COLLABORATION NEWS

Frequency Therapeutics

Entered into merger agreement with Korro Bio. combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs and will operate as Korro Bio.


AVROBIO

Is exploring strategic alternatives including acquisition, merger, business combination, or other transaction.


Infinity Pharmaceuticals

Stockholders have approved merger with MEI Pharma. The transaction remains subject to approval by MEI stockholders.


Eli Lilly

To acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling.

 

💡 Do you sell your products or services to biopharma companies?

BiopharmIQ MarketCompass is a market intelligence tool to help with your business development. Get a free sample report of potential targets.
bottom of page